Metabolic announces completion ofdosing in obesity trialFor...

Metabolic announces completion of
dosing in obesity trial
For Release: 20 September 2004
Metabolic Pharmaceuticals Limited is pleased to confirm that dosing in its
Phase 2b human clinical trial on obesity drug AOD9604 was completed last
Friday, 17 September 2004. The future timelines on this trial remain in
accordance with the dates advised in previous announcements.
Next Update
A shareholder update detailing key trial milestones and reporting dates, together
with recent developments, will be released to the market within the next week.
About Metabolic
Metabolic Pharmaceuticals Limited is a biotechnology company based in Melbourne, Australia,
and listed on the Australian Stock Exchange (ASX: MBP). The Company’s mission is to develop
a pipeline of new pharmaceuticals for world markets, and currently has active programs aimed at
treating obesity, pain and type 2 diabetes.
Background to AOD9604
AOD9604 for obesity is the company’s most advanced project, currently in Phase 2b human
clinical trials. The AOD9604 molecule is a small orally active peptide modelled on one part of
the human growth hormone molecule. Growth hormone naturally occurs in the body and has
profound stimulatory effects on fat metabolism, with levels of the hormone typically becoming
suppressed in the obese state. Daily dosing with AOD9604 restores suppressed fat metabolism in
the obese by mimicking the fat metabolic effects of growth hormone.
Metabolic believes that AOD9604 has the potential to provide a safer and more effective
pharmaceutical treatment for obesity than existing drugs. Previous short-term clinical trials
conducted on AOD9604, of up to one week’s duration, have indicated that the drug is orally
active, well tolerated and shows the expected trends in weight loss.